MedPath

ACCESS Trial Shows Promising Survival Rates with PTCy GVHD Prophylaxis in HLA-Mismatched Transplants

• Phase 2 ACCESS trial demonstrates 84% one-year overall survival rate using post-transplant cyclophosphamide for GVHD prevention in HLA-mismatched unrelated donor transplants.

• Study shows improved GVHD-free, relapse-free survival rate of 48% compared to 38% in previous 15-UUMD trial, marking significant progress in transplant outcomes.

• Results indicate successful outcomes regardless of number of HLA mismatches, potentially expanding treatment options for patients requiring stem cell transplantation.

The phase 2 ACCESS trial has achieved its primary endpoint, demonstrating promising survival outcomes for patients receiving post-transplant cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis in HLA-mismatched unrelated donor transplants.
The study, conducted in patients with hematologic malignancies, reported an impressive one-year overall survival rate of 84% among recipients of mismatched unrelated donor (MMUD) peripheral blood stem cell transplantation with PTCy prophylaxis. This marks a significant improvement from the previously reported 72% survival rate in the phase 2 15-UUMD trial.

Enhanced Survival Outcomes

The ACCESS trial (NCT04904588) showed notable progress in GVHD-free, relapse-free survival, achieving a rate of 48% compared to 38% in the earlier 15-UUMD study. Importantly, researchers observed comparable survival and GVHD outcomes regardless of whether patients had single or multiple HLA mismatches.

Clinical Implications and Treatment Strategy

Dr. Jeffery J. Auletta, Chief Scientific Director at the Center for International Blood and Marrow Transplant Research, emphasized the significance of these findings, particularly given that peripheral blood stem cells represent the most common transplant source. The study's success opens new possibilities for expanding myeloablative conditioning to a broader patient population.
"By leveraging myeloablative conditioning in combination with MMUD transplantation, high-dose chemotherapy can also provide a graft-vs-leukemia effect to enhance disease control," explained Dr. Auletta. This dual-action approach combines chemotherapeutic and immune-mediated mechanisms to eliminate malignant cells while establishing donor-derived immunity.

Treatment Protocol

The trial utilized myeloablative conditioning followed by peripheral blood stem cell transplantation, with PTCy administered as GVHD prophylaxis. This protocol demonstrates the feasibility of performing successful transplants even in cases with multiple HLA mismatches, potentially expanding the donor pool for patients requiring stem cell transplantation.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Clinical Trials

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

NCT02793544CompletedPhase 2
Center for International Blood and Marrow Transplant Research
Posted 12/1/2016

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

NCT04904588RecruitingPhase 2
Center for International Blood and Marrow Transplant Research
Posted 9/30/2021

Related Topics

Peri-Transplant Ruxolitinib Significantly Reduces GVHD Risk in Myelofibrosis Patients

A phase 2 study at Fred Hutchinson Cancer Center demonstrates that peri-transplant ruxolitinib combined with standard GVHD prophylaxis reduces acute GVHD incidence to 32%, compared to 71% with pre-transplant treatment.
The trial showed impressive survival rates, with 100% overall survival at 1 year and 87% at 2 years, while maintaining low chronic GVHD rates of 12% at 1 year.

Phase 2 Trial Shows Promising Results for Cord Blood Transplantation in Blood Cancer Patients

Unrelated umbilical cord blood transplantation demonstrated a 74% two-year overall survival rate in patients with hematologic malignancies, with particularly strong outcomes in pediatric patients.
The study showed notably low relapse rates of 11% in patients with minimal residual disease-positive acute leukemia, highlighting cord blood's unique benefits as a donor source.

Palisade Bio Advances PALI-2108 for Ulcerative Colitis Treatment into Multiple Ascending Dose Study

Palisade Bio has initiated the multiple ascending dose (MAD) cohorts of its Phase Ia/b trial for PALI-2108 in ulcerative colitis after completing single ascending dose (SAD) cohorts.
Preliminary data from the SAD cohorts showed PALI-2108 was well-tolerated across doses from 15mg to 450mg, with no serious adverse events reported.

Orca-T Demonstrates Promising Outcomes in Hematologic Malignancies

Orca-T, an allogeneic T-cell immunotherapy, shows safety and feasibility in reduced-intensity stem cell transplant for advanced hematologic malignancies.
A retrospective analysis indicates improved overall survival with Orca-T compared to post-transplant cyclophosphamide in high-risk patients.

Padeliporfin VTP Shows Promise in Phase 3 Trial for Low-Grade UTUC

Interim data from the ENLIGHTED phase 3 trial reveals padeliporfin vascular targeted photodynamic (VTP) therapy demonstrates notable safety and efficacy in treating low-grade upper tract urothelial carcinoma (UTUC).
The study reported an 86% complete response rate among patients who completed the induction treatment phase, suggesting a potential paradigm shift in UTUC management.

Ultimovacs' UV1 Fails to Improve Outcomes in Head and Neck Cancer Trial

The Phase II FOCUS trial evaluating Ultimovacs' UV1 vaccine plus pembrolizumab in head and neck squamous cell carcinoma (HNSCC) did not meet its primary endpoint of improving progression-free survival.
Secondary endpoints, including overall survival, also did not demonstrate a clinical benefit with the addition of UV1 to pembrolizumab.

CAST Regimen Improves Outcomes in Half-Matched Stem Cell Transplants

A new CAST regimen, combining post-transplant cyclophosphamide, abatacept, and tacrolimus, shows promise in preventing graft-versus-host disease (GVHD) after haploidentical hematopoietic stem cell transplantation (HSCT).
The CAST regimen demonstrated a statistically significant reduction in relapse rates and improved disease-free survival compared to the standard GVHD prevention regimen.

Outcomes Remain Poor for Myeloproliferative Neoplasm Blast Phase Despite New Therapies

A recent study in _Blood Advances_ highlights that the median overall survival for patients with myeloproliferative neoplasm blast phase (MPN-AP/BP) remains poor at 0.86 years, despite modern therapies.
The research found no significant difference in survival based on first-line treatment strategies, including intensive chemotherapy and venetoclax-based regimens, indicating a lack of optimal pre-transplant strategy.

CAP-1002 Shows Sustained Cardiac Benefit in Duchenne Muscular Dystrophy

Data from the HOPE-2 open-label extension study demonstrate that CAP-1002 continues to improve left ventricular ejection fraction (LVEF) in DMD patients over two years.
Patients treated with CAP-1002 exhibited statistically significant benefits in the Performance of the Upper Limb (PUL v2.0) scale compared to the decline observed in the placebo group.

Final 5-Year Results of the Phase 2 PACE Trial for CML and Ph+ ALL Patients

The PACE trial's final 5-year results demonstrate ponatinib's efficacy and safety in treating chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients who have undergone prior therapies. The study highlights significant response rates, durability of responses, and the impact of dose adjustments on maintaining efficacy while managing adverse events.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy